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Abstract
Background: Chloroquine (CQ) has been in use in Africa for a long time. Because of misuse, this drug
has now lost its efficacy due to the emergence of resistance strains in most parts of Africa. Recently, it was
shown that after chloroquine has been withdrawn from the market, chloroquine-sensitive Plasmodium
falciparum re-emerged and chloroquine could again be used successfully as an antimalarial. Surveillance of
parasite populations is, therefore, important to decide whether chloroquine could be re-introduced.
Methods: To estimate the prevalence of the most pivotal polymorphisms, including Pfcrt K76T, Pfmdr1
N86Y and Pfmdr1 Y184F mutations, and their contributions to the outcome of CQ treatment, isolates
from Osogbo Western Nigeria were tested using the Fluorescence Resonance Energy Transfer (FRET)
method on a real-time PCR instrument.
Results: 116 children with acute uncomplicated P. falciparum malaria infections were treated with the
standard dosage of CQ and followed-up for 28 days. Blood samples were collected on filter paper at
enrollment and during follow-up for identification of parasite carrying the chloroquine resistant
transporter (pfcrt) and P. falciparum-multi drug resistance (pfmdr1) gene mutations. Parasitological
assessment of response to treatment showed that 62% of the patients were cured and 38% failed the CQ
treatment. The presence of single mutant pfcrt (T76) alleles (P = 0.003) and in combination with mutant
pfmdr1 Y86 (P = 0.028) was significantly associated with in vivo CQR. No other mutation on its own or in
combinations was significantly associated with treatment outcome. Mutant pfcrt was more prevalent in
both pre- and post-treatment isolates. No association was observed between age or initial level of
parasitaemia and chloroquine treatment outcome.
Conclusion: The result established the usefulness and accuracy of real time PCR in pfcrt and pfmdr1
mutation detection and also give further evidence to the reliability of the pfcrt T76 point mutation as a
molecular marker for CQ resistance.
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Background
While there is an active search for new antimalarial drug
combinations that could prevent or delay further spread
of resistance, there is a need to understand the basis of
parasites resistance to chloroquine (CQ) and other anti-
malarial drugs and explore potentials to use the data in
improving the potency and rational for selecting compo-
nents for effective drug combination. Constant observa-
tion of the existing parasite population concerning their
genetic makeup determining the resistance to CQ became
even more important since it was shown that after CQ
withdrawal for therapy CQ-sensitive parasite re-occurred
[1]. So written-off drugs may come into focus again.
The molecular basis of CQ resistance in Plasmodium falci-
parum is still unclear, and the association of point muta-
tions in different genes with chloroquine-resistance has
been largely studied in the last decade. In 2000, pfcrt gene
was identified [2]. This gene consisting of 13 exons
showed 6–8 point mutations including one that appears
to play a crucial role in CQR [3]. A lysine to threonine
change at position 76 (K76T) which was subsequently
found in every in vitro CQR parasite from around the
world [4,5] was identified as an important mutation asso-
ciated with CQR. The resistance was associated with a
reduced accumulation of CQ in the parasite digestive vac-
uole but how the pfcrt gene exerts such an effect on the
digestive vacuole is still unclear. Many studies have shown
that the pfcrt play a crucial on CQR, but this mutation was
not the sole requirement, suggesting that other factors
including host factors are responsible for the clearance of
CQR parasites [6].
Polymorphisms in pfmdr1, a gene located on chromo-
some 5 which encodes the P. falciparum P-glycoprotein
homologue-1 is also thought to modulate CQR. It is a typ-
ical member of the ATP-binding cassette transporter
superfamily localized in the parasite vacuole, where it
may regulate intracellular drug concentrations [7]. Muta-
tions were observed at the amino acids 86, 184, 1034,
1042, and 1246, which were strongly linked to the CQR
in laboratory clones obtained from various regions [8].
However, the link between pfmdr1 and CQR still remains
unclear and controversial [6,9]. While some field studies
had indicated that there is positive association between
CQR and mutation (asparagine to tyrosine change) at
position 86 (N86Y) [10,11], several others had doubts
about this association [12,13]. Currently, pfmdr1 muta-
tions are said to assist the CQR parasites by augmenting
the level of resistance. A combination of pfcrt and pfmdr1
polymorphisms is believed to result in higher levels of
CQR [4,7].
In Nigeria, CQ has been used for many years as the first-
line treatment for uncomplicated malaria. However, like
many other malaria endemic regions the therapeutic effi-
cacy of CQ has decreased considerably. This, therefore,
has led to the change in the first line drug for the treat-
ment of malaria to artemisinin-based combination,
although, CQ is still widely used in the country. In order
to explore the roles of pfcrt and pfmdr1 polymorphisms in
CQR, the Fluorescence Resonance Energy Transfer (FRET)
method was used to determine these polymorphisms and
their in vivo sensitivity to chloroquine in P. falciparum iso-
lates from Osogbo Western Nigeria. The use of a Real
Time PCR assay for a rapid, sensitive, and specific detec-
tion of these mutations was also assessed.
Materials and methods
Study site and patients
The study was undertaken between July 2004 and January
2005 in the town of Osogbo located in the western part of
Nigeria. Osogbo is the state capital of Osun state Nigeria
and it represents a typical urban setting in Nigeria. Malaria
is present throughout the year with a marked increase dur-
ing the raining season (i.e. April – September). Febrile
children (1–12 years old) attending the Osun state Hospi-
tal and Ladoke Akintola University Teaching hospital
were screened for P. falciparum parasitaemia. Blood films
were stained with 10% Giemsa and examined microscop-
ically. Criteria for recruitment in this study were: (1) asex-
ual parasitaemia between 2,000/μl and 200,000/μl, (2)
no signs of severity or severe malaria (including severe
anaemia defined by haemoglobin <5 g/dl), (3) no intake
of antimalarial drugs during the preceding four weeks, (4)
informed consent from the patient parent or guardian.
The detected parasitaemic cases were treated with 25 mg/
kg chloroquine in divided doses for three days at 10 mg/
kg daily for D0 and D1 and 5 mg/kg for D2. Subsequent
follow up appointments were scheduled for days 3, 7, 14,
21 and 28.
Classification of responses to treatment was done accord-
ing to the WHO criteria [14]. The cure rate on day 28 of
the follow-up was defined as the percentage of children
who remained free of parasites. Two drops of blood were
also blotted onto 3 MM Whatman filter paper on days 0
before treatment and during following up when there was
re-occurrence of clinical symptoms for extraction and
analysis of parasites DNA. Treatment failure rates were
corrected by msp-2 genotyping of parasites at enrollment
and recrudescence of infections [15]. The study received
ethical approval from the ethical review committee
boards of the joint College of Health Sciences/Ladoke
Akintola University Teaching Hospital and Osun State
Hospitals Management Board.
Detection of Pfcrt and Pfmdr1 mutations by Real time PCR
Parasite genomic DNA was extracted from blood samples
collected on filter paper using a QIAamp DNA blood kitMalaria Journal 2007, 6:41 http://www.malariajournal.com/content/6/1/41
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(Qiagen, Hilden, Germany), according to the manufac-
turer's instructions. The oligonucleotide probes and
primer used to detect the polymorphisms in pfcrt  and
pfmdr1 are shown in Table 1.
For pfcrt analysis the sensor probe labeled with fluorescein
at the 3' end is designed to be perfectly complementary to
the mutation site. An amplification primer iLC labeled
with Cy5 on the third base from the 3'end is used as a
reverse primer which is extended during amplification.
During FRET, fluorescein which is excited by the light
source of the Rotor Gene instrument transfers its energy to
the Cy5 incorporated into the PCR product working as
anchor probe [16,17]. A specific melting temperature is
then obtained for each genotype: a sensor probe spanning
one mismatch could still hybridize to the target sequence
but will melt off at lower temperature than a sensor probe
with a perfect match. Primers and probes for pfcrt were
designed and synthesized by TIB MOLBIOL (DNA synthe-
sis service, Berlin, Germany)
For pfmdr1 mutations, hybridization probes consisted of
two different oligonucleotides that bind to an internal
sequence amplified by forward and reverse primers Table
1. The sensor probe, labeled at the 3'end with FAM, is
designed to match the mutation sites. The anchor probe,
labeled at the 5' end with Cy5 and phosphorylated at the
3' end to prevent extension by Taq polymerase, is
designed to conserved sequences adjacent to the mutation
sites. Both probes, localised on the same DNA strand,
could hybridize in a head-to tail arrangement, bringing
the two fluorescent dyes into close proximity. During
FRET, FAM was excited by the light source of the Rotor
Gene instrument. The excitation energy was transferred to
the acceptor fluorophore, Cy5, and the emitted fluores-
cence was measured on the Rotor Gene channel in contin-
uous during the melting phase. A specific melting
temperature is then obtained for each genotype as
described above. Pfmdr1 primers and probes were synthe-
sized by Operon Biotechnology (Cologne, Germany).
PCR amplification
Amplification was performed with Rotor Gene 3000
(Corbbett, Sydney, Australia). For pfcrt forward primer
was added at a final concentration of 0.4 μM, iLC primer
0.5 μM and probe at 0.2 μM. The amplification program
consisted of an initial step at 95°C for 10 min, amplifica-
tion was performed with 40 cycles of denaturation (95°C
for 10 s), annealing (50°C for 15 s), and extension (65°C
for 15 s). The melting curve program consisted of one
cycle of 95°C for 15 s, and heating at 36°C to 75°C rising
by 1°C.
For pfmdr1, the master mix contains a final concentration
of 0.4 μM of both primers and 0.2 μM of both Anchor and
sensor probes. For pfmdr1 codons 86 and 184, the PCR
program was as follows: 5 min at 95°C, 40 cycles of 94°C
for 10 s, 52°C for 30 s, and 72°C for 40 s. The melting
program consisted of one cycle of 95°C for 15 s and heat-
ing from 36 to 85°C rising by 1°C.
Statistical analysis
For analysis purposes, each isolate was classified based on
the presence or absence of a resistance-associated allele
and infections with mixed wild-type/mutant alleles of
pfcrt or pfmdr1 were treated as mutants. Data were ana-
lysed using the statistical programs JMP for Windows. For
univariate analysis, frequencies were compared using the
Fisher's exact tests. Two sided P values < 0.05 indicated
statistical significance. McNemar's test was used to com-
pare the samples before and after treatment.
Results
Patient treatment outcome
The potential for detection of a point mutation in pfcrt
and pfmdr1 genes using hybridization probes on Rotor
Gene technology has been evaluated. DNA from 116 sam-
ples of patients treated with chloroquine and successfully
followed up for 28 days were evaluated for pfcrt  and
Pfmdr1 (86 and 184) mutations.
Of these, 69 (59%) were males and 47 (41%) were
females. The mean age of the children was 46 ± 36 months
(6–144 months). Geometric mean parasite density was
9,061 parasites/μl of blood on the day of enrollment.
While infections in 72 (62%) of the patients were cured
with a standard dosage of CQ, 44 (38%) failed to respond
to treatment. The clinical data and therapeutic responses
of the patients stratified by age is shown in Table 2.
Real-time PCR for Pfcrt and Pfmdr1 gene detection in 
blood samples
Wild-type and mutant alleles were rapidly determined by
comparing the melting temperature for the alleles with
the melting temperature of the reference alleles obtained
by the FRET assay. The reference strains used for this study
were 3D7, FCR, S007 and K1 laboratory strains which
were all sequenced to determine the mutations that were
present. A confirmed field sample of Plasmodium malariae
was used as control along with no template. P. falciparum
strain K1 parasites were kindly provided by Katja Becker
(Justus-Liebig-University Giessen). Both 3D7 and FCR
showed the wild type sequence for pfcrt (K76) and Pfmdr1
(N86 and Y184). K1 showed mutant nucleotide at posi-
tion 76 (T76) for Pfcrt and position 86 (Y86) for pfmdr1
while S007 showed mutation at positions 76 for pfcrt, 86
and 184 for pfmdr1. DNA yielded a specific melting tem-
perature of 46.5 ± 0.3°C for the pfcrt mutant alleles and
65.3 ± 0.4 for the wild alleles. The melting temperaturesMalaria Journal 2007, 6:41 http://www.malariajournal.com/content/6/1/41
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for all the alleles are shown in Table 1. The melting anal-
ysis is shown in Figures 1&2
Association between Pfcrt and Pfmdr1 mutations and 
chloroquine treatment failure
The prevalence of Pfcrt T76 and Pfmdr1 (Y86 and F184)
mutations known to be involved in CQR resistance in
West Africa was evaluated. By in-vivo testing, 38% of the P.
falciparum isolates were chloroquine resistant, although
by molecular analysis 74% of the pre-treatment isolates
carried the mutant pfcrt  T76 and 14% had mixed
(T76+K76) allele that has been associated with chloro-
quine resistance in other studies [6,18]. The pfmdr1 Y86
and F184 alleles were present in 29% and 64% of the pre-
treatment isolates, respectively (Table 3).
The hypothesis whether allelic variations in pfcrt  and
pfmdr1 of P. falciparum isolates are associated with CQ
treatment outcome was tested in the study area. The pres-
ence of pfcrt or pfmdr1 mutations or the combination of
these mutations in samples collected before chloroquine
treatment was examined for their association with patient
treatment outcome. The pfcrt K76T allele was significantly
associated with CQ treatment failure (P = 0. 003). Both
pfmdr1  N86Y and Y184F did not show any significant
association. The combination of pfcrt 76 and pfmdr1 86
also produces weak significant association (p = 0.028)
(Table 3).
For analysis of parasites strains before and after treatment,
44 pairs was collected; each consisting of the parasite
strain before treatment and that from the recrudescence
infection. All the 44 samples had either mutant or mixed
T76 allele in their pre-treatment sample and 43/44 (98%)
had the mutant pfcrt allele after treatment. Only one iso-
late showed the wild pfcrt allele and genotyping by MSP2
confirmed the isolate to be a new infection. For Pfmdr1
Y86 and F184 the prevalence of the alleles at pre-treat-
ment isolates were 17% and 33%, respectively, and at
recrudescence the prevalence of Y86 was 18% while that
of F184 was 27%. The analysis of nonresponding and
recrudescent parasites showed a pronounced significant
difference between the samples collected before and after
chemotherapy for the isolates having pfmdr1 F184 muta-
tion (p = 0.031) while for other alleles tested there was no
Table 2: Enrollment clinical data and therapeutic responses of patients with acute uncomplicated Plasmodium falciparum treated with 
chloroquine stratified by age
Age Freq Sex Temp  Mean  Mean Mean  T76  Y86  F184  CQ  Treatment   
(Yrs) M F (SD) PD FC PC (%) (%) (%) Cured Failed
0<4 72 39 33 37.7 (± 1.13) 8261.066 2.7 2.6 67 (93%) 27 (38%) 49 (68%) 46 (58%) 26 (36%)
4<8 27 20 7 38.0 (± 1.3) 11632.6 1.2 2.4 22 (81%) 9 (33%) 20 (74%) 17 (63%) 10 (37%)
8–12 17 10 7 37.8 (± 0.84) 9015.282 1.3 2.5 16 (94%) 6 (35%) 12 (71%) 9 (53%) 8 (47%)
Total 116 69 47 37.8 (± 1.3) 9061.375 1.7 2.5 102 (88%) 42 (36%) 81 (70%) 72 (62%) 44 (38%)
Key: Freq = Frequency
SD = Standard deviation
PD = Parasite density on Day 0
FC = Fever clearance time in days
PC = Parasite clearance time in days
Table 1: Sequence of primers and probes used for Pfcrt and Pfmdr1 amplification and melting temperatures of the sensor probes of 
each allele
Melting temperatures (°C) of the sensor probes
Sequence 5' to 3' Wild Mutant
Pfcrt
Forward Primer: CTTGTCTTGGTAAATGTGCTCA
iLC Primer: GTTACCAATTTTGTTTAAAGTTCT
Sensor Probe: TGTGTAATTGAAACAATTTTTGCTAA 46.5 ± 0.2 65.3 ± 0.4
Pfmdr1
Forward Primer: TGTATTATCAGGAGGAACATTACC
Reverse Primer: ACCACCAAACATAAATTAACGGA
Sensor Probe 86: ATTAATATCATCATAAATACATG 51.8 ± 0.3 56.5 ± 0.2
Anchor Probe 86: TCTTTAATATTACACCAAACACAGATAT
Sensor Probe 184: TAAAAAATGCACGTTTGACTTTATGTATTA 53.0 ± 0.2 58.7 ± 0.3
Anchor Probe 184: CCTTTTTAGGTTTATTTATTTGGTCATMalaria Journal 2007, 6:41 http://www.malariajournal.com/content/6/1/41
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significant difference between the pre and post treatment
samples Table 4.
Discussion
In this study, a Real Time PCR assay for the detection of
pfcrt and pfmdr1 alleles thought to be associated with CQ
susceptibility and resistance was described. This Real-
Time PCR assay was demonstrated to be rapid, sensitive,
and specific for the detection and characterization of P.
falciparum  genetic marker of CQR. The assay detected
mixed alleles infections and clearly discriminated
between CQ-susceptible and CQ-resistant isolates. Its
speed (up to 72 samples can be assayed in a 2-h experi-
ment) and performance characteristics may eliminate the
need for more complicated approaches and make it an
attractive strategy that could easily be adapted to large-
scale studies of drug resistance.
Point mutations in the pfcrt gene and to a lesser extent, in
the pfmdr1 gene are thought to be associated with CQR
[2,6]. The goal of this study was to evaluate the utility of
these molecular markers as indicators of chloroquine
resistance in isolates of P. falciparum obtained from
Osogbo western Nigeria using a hybridization probe
method on a Real Time PCR technology platform. The
result of this study showed a high prevalence of pfcrt T76
(74%). This observation is consistent with the previous
reports from various malaria endemic regions where chlo-
roquine has been widely used. A significant association
was also found between the overall in vivo rate of treat-
Example of a typical real time rum showing melting curve analysis of Pfcrt position 76 Figure 1
Example of a typical real time rum showing melting curve analysis of Pfcrt position 76.
 K76 
 T76 
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ment failure and the frequency of mutated pfcrt gene in
the population (P = 0.004) as already shown previously in
western Nigeria [19] and other malaria endemic areas
[18]. 93% of the pre-treatment isolates carried the pfcrt
T76 and mixed allele while among the post treatment iso-
late the prevalence was 98%. The facts that this polymor-
phism was present in all the recrudescence isolates
emphasised again the fact that this mutation is important
in CQR.
The point mutation of asparagine to tyrosine at codon 86
of pfmdr1 has been associated with CQR in some studies
[8,9] but not in others [12]. In the present study, both the
pfmdr1 Y86 and F184 mutations showed no correlation
with resistance to chloroquine. Both the wild type and the
mutant alleles for each locus were present in both sensi-
tive and resistance isolates. Previously, an association was
established between chloroquine-resistance and alleles of
the pfmdr1 gene in laboratory isolates obtained from dif-
ferent parts of the world [8]. Others had considered
whether this association existed in parasite isolates
obtained directly from the field [9,20]. Their analysis
showed that African isolates predominantly possess poly-
morphism at two alleles, codon-86 and codon-184, with
a positive association, although incomplete, between
mutation of codon-86 and CQR. A similar association has
been found in several studies [4,11,21,22]. Nevertheless,
much confusion has surrounded the association of differ-
ent  pfmdr1  alleles to chloroquine resistance because
numerous studies have had contradictory results. Trans-
fection studies as well as carefully controlled molecular
epidemiologic studies have shown that there are strong
associations between pfmdr1 polymorphisms and antima-
larial resistance [7]. However, like many other studies [12]
the present findings have failed to find such associations
because the presence of both wild-type and mutant-type
alleles in our samples were largely independent of their in
vivo responses. Also the current belief that the combina-
tion of pfcrt and pfmdr1 polymorphisms result in higher
levels of CQR [4] was not observed in this study. Although
Example of a typical melting curve analysis generated by real time PCR of the Pfmdr position 86 Figure 2
Example of a typical melting curve analysis generated by real time PCR of the Pfmdr position 86.
Y86
N86
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a significant association was observed (p = 0.028), it was
not in any way stronger than the one observed with pfcrt
alone. Analysis of altered gene expression and other
mechanisms that may contribute to a resistant phenotype
is needed before the role of pfmdr1 can be excluded.
A recent report from Ibadan Nigeria a neighbouring town
to Osogbo had suggested an association and linkage dise-
quilibrium between the pfcrt T76 and pfmdr1 Y86 alleles
in chloroquine-resistant isolates [19]. On the contrary this
study suggested no possible association between these
two polymorphic alleles and in vivo chloroquine resist-
Table 3: Prevalence of pfcrt and pfmdr1 alleles in post-treatment samples of Nigerian children with acute uncomplicated malaria.
Allele Frequency Treatment outcome (%)
Cured N = 72 Failed N = 44 P. value
N = 116
Pfcrt T 76 86 (74%) 51 (71%) 41 (93%)
Pfcrt K 76 11 (12%) 11 (15%) 0 (0%) 0.003*
T76+K76 19 (14%) 10 (14%) 9 (20%)
N = 116
Pfmdr1 Y86 34 (29%) 22 (31%) 12 (27%)
Pfmdr1 N86 74 (64%) 47 (65%) 27 (61%) n.s.
Y86+N86 8 (7%) 3 (4%) 5 (11%)
N = 116
Pfmdr1 F184 74 (64%) 45 (63%) 29(65%)
Pfmdr1 Y 184 35 (30%) 24 (33%) 11 (25%) n.s.
F184+Y184 7 (6%) 3 (4%) 4 (9%)
N = 116
T76 + Y86 37 (32%) 21 (29%) 16 (36%)
K76 + N86 7 (6%) 7 (10%) 0 (0%) 0.028*
Mixed 72 (62%) 44 (61%) 28 (64%)
N = 116
T76 + F186 73 (63%) 40 (56%) 33 (75%)
K76 + Y184 2 (2%) 2 (3%) 0 (0%) n.s.
Mixed 41 (35%) 30 (42%) 11 (25%)
N = 116
T76+Y86+F184 35 (30%) 19 (26%) 16 (36%)
K76+N86+Y184 3 (3%) 3 (4%) 0 (0%) n.s.
Mixed 78 (67%) 50 (70%) 28 (64%)
n.s. is not significant
Table 4: Prevalence of mutant pfmdr1/pfcrt genes in Day 0 and recrudescence samples of patients that failed chloroquine treatment
Prevalence of alleles
Alleles Day 0 Recrudescence Mc Nemar P value
T76 44/44 (100%) 43/44 (98%) 1
Y86 17/44 (39%) 18/44 (41%) 1
F184 33/44 (75%) 27/44 (61%) 0.031*
T76+Y86 44/44 (100%) 43/44 (98%) 1
T76+F184 44/44 (100%) 43/44 (98%) 1
T76+Y86+F184 44/44 (100%) 44/44 (100%) 1
Mixed infection is considered as mutant
*Significant at P < 0.05Malaria Journal 2007, 6:41 http://www.malariajournal.com/content/6/1/41
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ance and that these molecular markers by themselves may
not predict in vivo chloroquine resistance.
Conclusion
In summary, the results of this study give further evidence
to the reliability of the 76T pfcrt  point mutation as a
molecular marker for CQ resistance. Conversely, the role
of the Y86 and F184 point mutation of pfmdr1 gene in CQ
resistance remains elusive. The analysis of the relevant
mutations by RT-PCR provides a rapid and reliable
method for epidemiological and clinical studies suited for
higher throughput.
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